Literature DB >> 24919264

[Topoisomerase IIa expression in correlation with clinical and morphological parameters and proliferation (based on argyrophilic proteins of nucleolar organizer regions and Ki-67 antigen) in lung adenocarcinoma].

D S Kodiakov, V V Klimachëv, A M Avdalian, I P Bobrov, A F Lazarev, E L Lushnikova, L M Nepomiashchikh.   

Abstract

Investigated topoisomerase IIalpha (TopoII alpha), argyrophilic proteins associated with nucleolar organizer regions (Ag-NOR) and antigen Ki-67 in lung adenocarcinoma. Defined tumor with low and high TopoII alpha, Ag-NOR and Ki-67. TopoII alpha had a relationship with clinical and morphological parameters (greatest dimension, tumor differentiation) and proliferation markers (Ag-NOR, Ki-67) . Survival of patients with lung adenocarcinoma with low content of TopoII alpha is better as compared with high content of TopoII alpha. Survival of patients with lung adenocarcinoma depends on the mutual content of TopoII alpha and clinical and morphological parameters (value T, greatest dimension, value N, stage, tumor differentiation), proliferation markers (Ag-NOR). TopoII alpha content in lung adenocarcinoma is an independent prognostic factor. Mutual research of TopoII alpha with clinical and morphological parameters and Ag-NOR has prognostic value in lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24919264

Source DB:  PubMed          Journal:  Vopr Onkol        ISSN: 0507-3758


  2 in total

1.  Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese.

Authors:  Tian-Lu Wang; Yang-Wu Ren; He-Tong Wang; Hong Yu; Yu-Xia Zhao
Journal:  Med Sci Monit       Date:  2017-02-23

2.  Integrative analysis of mRNA and miRNA expression profiles reveals seven potential diagnostic biomarkers for non‑small cell lung cancer.

Authors:  Jie Zhang; Dong Li; Yueming Zhang; Zongli Ding; Yulong Zheng; Song Chen; Yufeng Wan
Journal:  Oncol Rep       Date:  2019-11-13       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.